The trial evaluated Tagrisso in patients with Stage IB, II, IIIA epidermal growth factor receptor-mutated non-small cell lung cancer. Credit: eggeegg /Shutterstock.com.

AstraZeneca has reported positive results from the ADAURA Phase III trial of Tagrisso (osimertinib) in the adjuvant treatment of patients with Stage IB, II, IIIA epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC).

The global, placebo-controlled, randomised, double-blind study has enrolled 682 patients across more than 20 countries including the US, Europe, Asia, South America, and the Middle East.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Patients with Stage IB, II, IIIA EGFRm NSCLC following complete tumour resection and adjuvant chemotherapy were administered with Tagrisso 80mg once-daily oral tablets or placebo for three years or until disease recurrence.

The primary endpoint of the trial was DFS in Stage II and IIIA patients while key secondary endpoints included DFS in Stage IB, II and IIIA patients, and overall survival (OS) in both the primary and overall populations.

Tagrisso reduced death risk by 51% compared to placebo in both the primary analysis and the overall trial populations.

See Also:

The study demonstrated a statistically significant and clinically meaningful improvement in OS against placebo in the adjuvant treatment.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

AstraZeneca Oncology research and development executive vice-president Susan Galbraith: “Tagrisso cut the risk of death by more than half in the adjuvant setting, further establishing this transformative medicine as the backbone treatment for EGFR-mutated lung cancer.

“These results emphasise the importance of diagnosing patients with lung cancer early, testing for EGFR mutations and treating all those with an EGFR mutation with Tagrisso.”

Tagrisso is also being tested in Phase III trials in the neoadjuvant resectable setting (NeoADAURA), in the Stage IA2-IA3 adjuvant resectable setting (ADAURA2) and the Stage III locally advanced unresectable setting (LAURA).